Press release
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
HOLON, Israel, March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in
About this update from Compugen Ltd.
HOLON, Israel , March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025 : H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference Date: Wednesday, April 2, 2025 Format: Fireside chat and 1x1 meetingsFireside chat time: 9:30 am ET 24th Annual Needham Virtual Healthcare Conference Date: Monday, April 7, 2025 Format: Fireside chat and 1x1 meetingsFireside chat time: 8:00 am ET Stifel's 2025 Virtual Targeted Oncology Forum Date: Wednesday, April 9, 2025 Format: Fireside chat and 1x1 meetingsFireside chat time: 12:00 pm ET Live webcasts of the fireside chats will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com . Replays will be available following the live events. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform ( Unigen TM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to enhance anti-cancer immunity. Compugen is headquartered in Israel , with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact: Yvonne Naughton , Ph.D.Head of Investor Relations and Corporate CommunicationsEmail: [email protected] Tel: +1 (628) 241-0071 View original content: https://www.prnewswire.com/news-releases/compugen-to-participate-in-multiple-virtual-investor-conferences-in-april-2025-302411894.html SOURCE Compugen Ltd.